Clinical Trial

Optimizing GVHD Prophylaxis After Allogeneic Hematopoietic Cell Transplantation

Study acronym: PTCYGVHD
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study will compare post-transplant health-related quality of life following the use of standard versus attenuated dose of post-transplant cyclophosphamide in addition to two-drug graft-versus-host disease (GVHD) prophylaxis among recipients of allogeneic hematopoietic stem cell transplant.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-01-22; most recent amendment 2025-12-08.
Status change: Not Yet Recruiting → Recruiting 2025-08-04
Trial Details
NCT Number NCT06799195
Lead Sponsor University of Nebraska
Conditions Hematological Malignancies, Graft-versus-Host Disease (GVHD)
Enrollment 126 participants
Start Date 2025-06-23
Primary Completion 2031-04 (estimated)
Study Completion 2031-11 (estimated)
Updated on ClinicalTrials.gov 2025-12-15